Home >> Signaling Pathways >> Apoptosis >> c-RET


The c-RET proto-oncogene, which was originally identified as a transforming gene by transfection of T-cell lymphoma DNA into NIH3T3 cells, is a member of the receptor tyrosine kinase (RTK) gene superfamily that encodes a receptor tyrosine kinase involved in the regulation of glial cell line-derived neurotrophic factor (GDNF) signaling. Signaling proteins, such as Grb7/Grb10, PLCγ, Shc/Enigma and Grb2, are recruited by activated c-RET protein through binding to the phosphorylated tyrosine residues in c-RET protein’s COOH-terminal sequence, Y905, Y1015, Y1062 and Y1096 respectively.  Moreover, results of in vivo studies suggest mutations of c-RET have been implicated in tumorigenesis, in which c-RET mRNA and/or protein have been found in tumors of neuroectodermal origin as well as in human neuroblastoma cell lines.

  1. Cat.No. Product Name Information
  2. C3080 AD57 (hydrochloride) polypharmacological cancer therapeutic that inhibits RET.
  3. A4237 Amuvatinib (MP-470, HPK 56) Tyrosine kinase inhibitor
  4. A4116 Danusertib (PHA-739358) Pan-aurora kinase inhibitor
  5. A8236 Regorafenib Inhibitor of VEGFR/PDGFR/FGFR/mutant kit/RET/Raf-1
  6. A3750 Regorafenib hydrochloride Tyrosine kinase inhibitor
  7. A3751 Regorafenib monohydrate Tyrosine kinase inhibitor
  8. C4239 RPI-1 ATP-dependent RET kinase inhibitor
  9. A3847 SU5416 VEGF receptor inhibitor and AHR agonist
  10. A4145 TG101209 JAK2/3 inhibitor

9 Item(s)

per page

Set Descending Direction